Integrated Investment Consultants’s Myriad Genetics MYGN Stock Holding History

Integrated Investment Consultants’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,712	Closed	-$184K	–	286
2022 Q4	$184K	Sell	12,712 -19	-0.1%	-$354	0.06%	236
2022 Q3	$243K	Hold	12,731	–	–	0.1%	180
2022 Q2	$231K	Buy	12,731 +39	+0.3%	+$810	0.08%	201
2022 Q1	$320K	Buy	12,692 +307	+2%	+$7.86K	0.09%	214
2021 Q4	$342K	Sell	12,385 -14	-0.1%	-$406	0.09%	209
2021 Q3	$400K	Buy	12,399 +152	+1%	+$5.05K	0.12%	162
2021 Q2	$375K	Sell	12,247 -3,129	-20%	-$90.4K	0.11%	168
2021 Q1	$468K	Buy	15,376 +4,500	+41%	+$128K	0.16%	119
2020 Q4	$215K	Buy	10,876 +13	+0.1%	+$210	0.08%	220
2020 Q3	$142K	Buy	+10,863	New	+$137K	0.07%	194

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Integrated Investment Consultants's MYGN Position: Q1 2023 in Review

Integrated Investment Consultants sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 12,712 shares — an estimated $184K sold.

Integrated Investment Consultants first reported a position in MYGN in Q3 2020 and held it in 10 quarters. The position peaked at $468K in Q1 2021. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

Integrated Investment Consultants reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
Integrated Investment Consultants sold 12,712 Myriad Genetics shares in Q1 2023, an estimated $184K.
Integrated Investment Consultants first reported a position in Myriad Genetics in Q3 2020 and held it in 10 quarters.
Integrated Investment Consultants's Myriad Genetics position peaked at $468K in Q1 2021.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Integrated Investment Consultants's 13F filing for Q1 2023, filed 18 Jul 2023.